To the full analysis
Divi's Laboratories stock: growth
DIVISLAB.NSDivi's Laboratories reported $1.12B in revenue for fiscal 2026, up 13.2% on the prior year, up 9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
15.1%
per year from 2007 to 2026, per share 14.9%
Earnings (Annual rate)
14.8%
per year from 2007 to 2026, per share 14.6%
Free cash flow (Annual rate)
15.6%
per year from 2007 to 2026, per share 15.4%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 9.0% | 10.9% | 15.1% |
| Revenue per share | 9.0% | 10.9% | 14.9% |
| Earnings | 5.3% | 8.6% | 14.8% |
| Earnings per share | 5.3% | 8.6% | 14.6% |
| Free cash flow | −13.7% | −2.5% | 15.6% |
| Free cash flow per share | −13.7% | −2.5% | 15.4% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $77.01M | $19.75M | $3.36M |
| 2008 | $1.1B | $36.95M | $12.9M |
| 2009 | $125.46M | $44.28M | $20.28M |
| 2010 | $100.08M | $36.17M | $32.86M |
| 2011 | $139.93M | $45.63M | $17.41M |
| 2012 | $198.11M | $56.68M | $5.23M |
| 2013 | $227.97M | $63.99M | $14.87M |
| 2014 | $269.14M | $82.2M | $32.98M |
| 2015 | $331.08M | $90.51M | $55.18M |
| 2016 | $400.6M | $119.66M | $68.25M |
| 2017 | $430.82M | $112.71M | $82.23M |
| 2018 | $404.69M | $93.22M | $53.35M |
| 2019 | $510.59M | $143.78M | $23.51M |
| 2020 | $562.39M | $146.31M | $3.48M |
| 2021 | $728.96M | $210.91M | $110.19M |
| 2022 | $935.26M | $314.66M | $127.4M |
| 2023 | $814.7M | $193.87M | $211.09M |
| 2024 | $828.63M | $170.06M | $27.42M |
| 2025 | $991.14M | $232.88M | $53.99M |
| 2026 | $1.12B | $272.95M | $52.83M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 10 Apr 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.